Oswald Bentinck

Company: Rocket Pharmaceuticals Ltd.

Job title: Vice President, Global Head of Value & Access

Bio:

Oswald currently serves as Global Head of Value and Access at Rocket Pharmaceuticals, a clinical-stage biotech, advancing an integrated pipeline of LVV & AAV genetic therapies that correct the root cause of complex and rare life-threatening childhood hematological disorders and cardiomyopathies. He joined Rocket in August 2022.

Before Rocket, Oswald was Head of Value and Access EMEA at AveXis/Novartis Gene Therapies that successfully launched Zolgensma, a gene therapy for spinal muscular atrophy (SMA). Earlier Oswald worked in various regional and global marketing and market access roles at Pfizer, Shire, and Alexion. He has over 20 years’ commercial experience in the pharmaceutical industry with 14 of those focusing on rare diseases.

Seminars:

The Critical Role of Market Access in Early Gene Therapy Development 2:30 pm

Engaging Market Access teams early to ensure pricing, reimbursement, and health system adoption challenges are addressed before costly late-stage hurdles arise Exploring how proactive Market Access strategies can shape clinical development, evidence generation, and payer engagement to maximize patient access and commercial successRead more

day: Conference Day One